|
| 31164653 | Author Correction: Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer. | Nat Commun | 2019 |
| 31582562 | The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity. | Journal of Biological Chemistry | 2019 |
| 30559381 | Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. | Nature | 2019 |
| 30386887 | Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA). | Cancer Chemotherapy and Pharmacology | 2019 |
| 30368584 | Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers. | Cancer Chemotherapy and Pharmacology | 2019 |
| 30635584 | Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators. | Nat Commun | 2019 |
| 29457796 | H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. | Nature Medicine | 2018 |
| 30137981 | Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. | Journal of Medicinal Chemistry | 2018 |
| 29991605 | Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα and ERα Breast Cancer. | Cancer Discovery | 2018 |
| 29247039 | H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma. | Cancer Research | 2017 |
| 28541300 | Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex. | Nat Commun | 2017 |
| 28329763 | The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. | Nature | 2017 |
| 28740126 | Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer. | Nat Commun | 2017 |
| 29296742 | Novel in-frame deletions result in aberrant RNA splicing in CLL patients. | Blood advances | 2017 |
| 29121062 | Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. | PLoS ONE | 2017 |
| 27362227 | Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. | Nature | 2016 |
| 26710000 | Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms. | Journal of Visualized Experiments | 2015 |
| 26565915 | Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. | Cell Rep | 2015 |
| 25058389 | NAMPT is the cellular target of STF-31-like small-molecule probes. | ACS Chem Biol | 2014 |
| 25376106 | Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line. | Org Lett | 2014 |
| 23742252 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. | J Med Chem | 2013 |
| 22130798 | Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL. | Blood | 2012 |
| 22460905 | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. | Nature | 2012 |
| 21949247 | Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. | Proc Natl Acad Sci U S A | 2011 |
| 21324920 | Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. | Cancer Research | 2011 |
| 21892161 | Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. | Nat Genet | 2011 |
| 20670954 | The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. | Cancer Research | 2010 |
| 24900187 | Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. | ACS Medicinal Chemistry Letters | 2010 |
| 21076395 | Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. | Nat Med | 2010 |
| 20881279 | Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. | Sci Transl Med | 2010 |
| 20930519 | Allosteric inhibition of BCR-ABL. | Cell Cycle | 2010 |
| 20928937 | Hedgehog pathway activation in chronic myeloid leukemia. | Cell Cycle | 2010 |
| 20530672 | The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. | Cancer Research | 2010 |
| 20604564 | A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. | J Med Chem | 2010 |
| 20072125 | Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. | Nature | 2010 |
| 20152788 | Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. | Biochim Biophys Acta | 2010 |
| 20237469 | Targeted cancer therapies in the twenty-first century: lessons from imatinib. | Clinical Pharmacology and Therapeutics | 2010 |
| 19150426 | A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. | Mol Cell | 2009 |
| 18772113 | Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. | Cancer Cell | 2008 |
| 23484970 | Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. | Expert Opinion on Drug Discovery | 2008 |
| 17960378 | Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. | Annals of Hematology | 2008 |
| 18667312 | Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. | Bioorg Med Chem Lett | 2008 |
| 17133113 | Ba/F3 cells and their use in kinase drug discovery. | Current Opinion in Oncology | 2007 |
| 17632527 | Essential role of stromally induced hedgehog signaling in B-cell malignancies. | Nature Medicine | 2007 |
| 17621874 | B-Raf kinase inhibitors for cancer treatment. | Current Opinion in Investigational Drugs | 2007 |
| 17668209 | Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner. | Annals of Hematology | 2007 |
| 17185414 | Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. | Proc Natl Acad Sci U S A | 2007 |
| 16492761 | An efficient rapid system for profiling the cellular activities of molecular libraries. | Proc Natl Acad Sci U S A | 2006 |
| 24980528 | Profiling the kinome for drug discovery. | Drug Discov Today Technol | 2006 |
| 16873026 | A general strategy for creating "inactive-conformation" abl inhibitors. | Chem Biol | 2006 |